Cargando…

731. Factors Contributing to Long-Term Risk of Developing Multidrug-Resistant Pseudomonas Recurrence

BACKGROUND: Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is a significant healthcare concern in hospitalized patients with a mortality rate upward of 54%. Delayed initiation of appropriate antibiotics with MDR infections may lead to prolonged hospital stays and increased mortality. Previous s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volker, Scott, Vogler, Andrew J, Fairman, Kathleen A, Huang, Vanthida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676946/ http://dx.doi.org/10.1093/ofid/ofad500.792

Ejemplares similares

731. Pharmacokinetics of Gepotidacin (GSK2140944) in Subjects with Hepatic Impairment
por: Hands, Jonathan T, et al.
Publicado: (2019)

731. Investigating Clinical Factors Contributing to Continued Antibiotic Therapy in Patients with Viral Upper Respiratory Tract Infections
por: Lawandi, Alexander, et al.
Publicado: (2018)

731. Puerperal Sepsis Among Women with In-facility Births in Western Tanzania
por: Smith, Rachel, et al.
Publicado: (2021)

731. The Emergence of Mobile Colistin Resistance (mcr) Genes among Enteric Pathogens in the United States — 2008–2019
por: Tobolowsky, Farrell A, et al.
Publicado: (2020)

731 Utility of Ceftaroline in the Treatment of Persistent Bacteremia and Deep-Seated Infections
por: Burgess, Donna R., et al.
Publicado: (2014)

PT731. A study of clinical factors related to intelligence diminution after onset of mental disorders
por: Oga, Kenichi, et al.
Publicado: (2016)

286. Prevalence and Clinical Outcomes of COVID-Associated Pulmonary Fibrosis
por: Vogler, Andrew J, et al.
Publicado: (2022)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

2180. Pseudomonas aeruginosa epidemic high-risk clones and their association with multidrug-resistant
por: Zurita, Jeannete, et al.
Publicado: (2023)

Ceftolozane-Tazobactam Resistance in Multidrug-Resistant Pseudomonas aeruginosa Isolates Not Associated with AmpC Activity
por: Tran, Truc T, et al.
Publicado: (2017)

Correction to Lancet Psychiatry 2020; 7: 731–33
Publicado: (2020)

ZTI-01 Treatment Improves Survival of Animals Infected with Multidrug Resistant Pseudomonas aeruginosa
por: Lawrenz, Matthew B, et al.
Publicado: (2017)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

547. Multidrug-Resistant Pseudomonas aeruginosa in an Academic Regional Burn Intensive Care Unit
por: Estelle, Carolee D, et al.
Publicado: (2019)

Polimixin B use in treatment of multidrug-resistant Pseudomonas aeruginosa infection
por: Gouveia, LS, et al.
Publicado: (2003)

726. Risk factor analysis for cefepime and piperacillin/tazobactam resistant organisms
por: Pham, Tho H, et al.
Publicado: (2023)

731 FAILURE TO DEVELOP NEUTRALIZING ANTIBODIES FOLLOWING SARS-COV-2 INFECTION IN YOUNG PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING BIOLOGICS
por: Dailey, Joelynn, et al.
Publicado: (2021)

Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China
por: Sun, Yanni, et al.
Publicado: (2017)

2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2018)

2769. Treatment of Hypermutator Pseudomonas aeruginosa Induces Multidrug Resistance but Can Be Targeted by Combination Therapy
por: Hall, Kalen M, et al.
Publicado: (2023)

1063. ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam
por: Mack, Andrew R, et al.
Publicado: (2021)

1506. Association of Antibiotic Treatment Duration with First Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients
por: Afolabi, Titilola M, et al.
Publicado: (2018)

349. Hardware-Associated Multidrug-resistant Pseudomonas aeruginosa Meningitis Treated with Ceftolozane-Tazobactam
por: Li, Caitlin, et al.
Publicado: (2020)

792. Outbreak of Multidrug-resistant Pseudomonas aeruginosa in a Tertiary Healthcare System in Detroit
por: Evans, Kenisha J, et al.
Publicado: (2021)

The promise and perils of Unit 731 data to advance COVID-19 research
por: Su, Zhaohui, et al.
Publicado: (2021)

2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance
por: Shields, Ryan K, et al.
Publicado: (2018)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

2382. Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
por: Elabor, Abdulrahman, et al.
Publicado: (2018)

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
por: McGovern, Paul C, et al.
Publicado: (2022)

Radical transfer in E. coli ribonucleotide reductase: a NH(2)Y(731)/R(411)A-α mutant unmasks a new conformation of the pathway residue 731
por: Kasanmascheff, Müge, et al.
Publicado: (2016)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)

1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa
por: Navas, Daniel, et al.
Publicado: (2020)

2435. Clinical Outcomes With Ceftolozane–Tazobactam in Patients With Multidrug-Resistant (MDR) Pseudomonas aeruginosa Bloodstream Infections: A Multi-Center Study
por: King, Madeline, et al.
Publicado: (2018)

2186. Treatment-emergent resistance to ceftazidime-avibactam (CZA) is more common than ceftolozane-tazobactam (CT) among patients infected with multidrug-resistant (MDR) Pseudomonas aeruginosa
por: Shah, Sunish, et al.
Publicado: (2023)

725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa
por: Mullane, Elias M, et al.
Publicado: (2019)

Effect of methylglyoxal on multidrug-resistant Pseudomonas aeruginosa
por: Hayashi, Katsuhiko, et al.
Publicado: (2014)

Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals
por: Telling, Kaidi, et al.
Publicado: (2018)

Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH)
por: Bojahr, Bernd, et al.
Publicado: (2015)

P24 Cefiderocol activity against a multidrug-resistant (MDR) strain of Pseudomonas aeruginosa: a case report
por: Lim,, Felicia H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3srru27ifonguouh4hke80071d